Orphan nuclear receptors as drug targets for the treatment of prostate and breast cancers
Authors:
- Mani Roshan-MoniriMRMani Roshan-Moniri
- Michael HsingMHMichael Hsing
- Miriam S. ButlerMBMiriam S. Butler
- Artem CherkasovACArtem Cherkasov
- Paul S. RenniePRPaul S. Rennie
- 1 December 2014
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 40 (10) , 1137-1152
Abstract
No abstract availableKeywords
Funding Information
- Canadian Institutes of Health Research (272111)
- Canada Safeway (SP2013-02)
This publication has 211 references indexed in Scilit:
- ZINC: A Free Tool to Discover Chemistry for BiologyJournal of Chemical Information and Modeling, 2012
- A long AAAG repeat allele in the 5′ UTR of the ERR-γ gene is correlated with breast cancer predisposition and drives promoter activity in MCF-7 breast cancer cellsBreast Cancer Research and Treatment, 2010
- Identification of SR1078, a Synthetic Agonist for the Orphan Nuclear Receptors RORα and RORγACS Chemical Biology, 2010
- Structure−Activity Relationship for Thiohydantoin Androgen Receptor Antagonists for Castration-Resistant Prostate Cancer (CRPC)Journal of Medicinal Chemistry, 2010
- Estrogen-related receptor alpha induces the expression of vascular endothelial growth factor in breast cancer cellsThe Journal of Steroid Biochemistry and Molecular Biology, 2009
- T Helper 17 Lineage Differentiation Is Programmed by Orphan Nuclear Receptors RORα and RORγImmunity, 2008
- Orphan nuclear receptors in drug discoveryDrug Discovery Today, 2007
- Inhibition of growth of cervical cancer cells using a dominant negative estrogen receptor geneGynecologic Oncology, 2007
- DAX1: Increasing complexity in the roles of this novel nuclear receptorMolecular and Cellular Endocrinology, 2007
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005